Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

Diabetes & endocrinologyPRM 0025
Dosage formTablets
Oral

Acarbose 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Local
Drugs Rules status
Schedule H cautionRule 96(1)(xi)
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 282
Diabetes & endocrinologyPRM 2590
Dosage formTablets
Oral

Acarbose 25 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Alpha-glucosidase inhibitor + Biguanide antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 0024
Dosage formTablets
Oral

Acarbose 50 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Local
Drugs Rules status
Schedule H cautionRule 96(1)(xi)
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 282
Diabetes & endocrinologyPRM 2591
Dosage formTablets
Oral

Acarbose 50 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Alpha-glucosidase inhibitor + Biguanide antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 2660
Dosage formTablets
Oral

Alogliptin 12.5 mg, Metformin 1000 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + DPP-4 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 2661
Dosage formTablets
Oral

Alogliptin 12.5 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + DPP-4 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 0104
Dosage formTablets
Oral

Alpha Lipoic Acid 200 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Drugs Rules status
Schedule GListed substance
CDSCO categoryFDC
Documented match

Listed in CDSCO FDC approval records

CDSCO filing reference · page 563
Diabetes & endocrinologyPRM 0221
Dosage formTablets
Oral

Atorvastatin 10 mg, Glimepiride 1 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Lipid-lowering agent
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Drugs Rules status
Schedules G & HListed in both schedules
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 0222
Dosage formTablets
Oral

Atorvastatin 10 mg, Glimepiride 2 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Lipid-lowering agent
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Drugs Rules status
Schedules G & HListed in both schedules
CDSCO categoryFDC
Documented match

Listed in CDSCO FDC approval records

CDSCO filing reference · page 553
Diabetes & endocrinologyPRM 3005
Dosage formTablets
Oral

Cabergoline 1 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Prolactin-lowering dopamine agonist
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3006
Dosage formTablets
Oral

Cabergoline 2 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Prolactin-lowering dopamine agonist
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3007
Dosage formTablets
Oral

Cabergoline 4 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Prolactin-lowering dopamine agonist
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3103
Dosage formTablets
Oral

Canagliflozin 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3104
Dosage formTablets
Oral

Canagliflozin 150 mg, Metformin 1000 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3105
Dosage formTablets
Oral

Canagliflozin 150 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3106
Dosage formTablets
Oral

Canagliflozin 150 mg, Metformin 850 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3107
Dosage formTablets
Oral

Canagliflozin 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3108
Dosage formTablets
Oral

Canagliflozin 50 mg, Metformin 1000 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3109
Dosage formTablets
Oral

Canagliflozin 50 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3110
Dosage formTablets
Oral

Canagliflozin 50 mg, Metformin 850 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Biguanide antidiabetic + SGLT2 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 0342
Dosage formTablets
Oral

Carbimazole 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Thyroid agent
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3157
Dosage formTablets
Oral

Cetilistat 120 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Pancreatic lipase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3239
Dosage formTablets
Oral

Cinacalcet 30 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcimimetic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 3240
Dosage formTablets
Oral

Cinacalcet 60 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcimimetic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product